Stocks and stories for the week...
AVNR: It's worth keeping an eye on Avanir Pharmaceuticals (AVNR) again with the stock trading well off its 52-week high after a slower than expected launch of Nuedexta, the company's treatment for pseudobulbar affect (PBA) approved by the FDA in late 2010. PBA is no...
With the "super committee" seemingly unable to come to a budget-cutting agreement this weekend, expect some volatility in the financial markets during the week ahead as the failure may trigger huge across-the-board cuts in government spending.
Regardless of the stalemate in Washington, here's some s...
Should the impressive results from Exact Sciences Corporation's (EXAS) colon and colorectal cancer detection diagnostic test continue through ongoing studies, this company could be positioned to set the standard for the future prevention and early detection of colorectal cancers, of which there are ...
The sluggish shares of Titan Pharmaceuticals...
A monumental decision by Geron Corporation...
Lpath, Ince. (OTC BB: LPTN), with milestone Phase II trials underway...
Shares of Titan Pharmaceuticals...
For months Ampio Pharmaceuticals (AMPE) has been releasing a steady dose of positive pipeline updates, which have included positive trial results for lead product Ampion in the treatment of osteoarthritis in the knee (OIK), and a licensing deal for Zertane in the treatment of premature ejaculation.
T...
For months Ampio Pharmaceuticals (AMPE) has been releasing...
By targeting the potential high growth markets of South Africa...
You've got to laugh at the market hype created by the media...